| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1844* | 2021 |
| Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade KE Pauken, MA Sammons, PM Odorizzi, S Manne, J Godec, O Khan, ... Science 354 (6316), 1160-1165, 2016 | 1154 | 2016 |
| HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications O Khan, NB La Thangue Immunology and cell biology 90 (1), 85-94, 2012 | 538 | 2012 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 446* | 2021 |
| Arginine methylation controls growth regulation by E2F‐1 EC Cho, S Zheng, S Munro, G Liu, SM Carr, J Moehlenbrink, YC Lu, ... The EMBO journal 31 (7), 1785-1797, 2012 | 261 | 2012 |
| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 248 | 2022 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 241 | 2022 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 236 | 2022 |
| HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy O Khan, S Fotheringham, V Wood, L Stimson, C Zhang, F Pezzella, ... Proceedings of the National Academy of Sciences 107 (14), 6532-6537, 2010 | 191 | 2010 |
| Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis AR Hussain, SO Ahmed, M Ahmed, OS Khan, S Al AbdulMohsen, ... PloS one 7 (6), e39945, 2012 | 183 | 2012 |
| Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis S Fotheringham, MT Epping, L Stimson, O Khan, V Wood, F Pezzella, ... Cancer cell 15 (1), 57-66, 2009 | 168 | 2009 |
| HDAC inhibitor-based therapies and haematological malignancy L Stimson, V Wood, O Khan, S Fotheringham, NB La Thangue Annals of oncology 20 (8), 1293-1302, 2009 | 163 | 2009 |
| Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer R Bagatell, O Khan, G Paine-Murrieta, CW Taylor, S Akinaga, L Whitesell Clinical Cancer Research 7 (7), 2076-2084, 2001 | 158 | 2001 |
| Competitive binding of xenobiotic oestrogens to rat alpha-fetoprotein and to sex steroid binding proteins in human and rainbow trout (Oncorhynchus mykiss) plasma SR Milligan, O Khan, M Nash General and comparative endocrinology 112 (1), 89-95, 1998 | 142 | 1998 |
| Follicular helper T cells: new insights into mechanisms of autoimmune diseases X Zhang, S Ing, A Fraser, M Chen, O Khan, J Zakem, W Davis, R Quinet Ochsner journal 13 (1), 131-139, 2013 | 115 | 2013 |
| The role of the kynurenine pathway in suicidality in adolescent major depressive disorder KAL Bradley, JAC Case, O Khan, T Ricart, A Hanna, CM Alonso, ... Psychiatry research 227 (2-3), 206-212, 2015 | 114 | 2015 |
| Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas O Khan, NB La Thangue Nature Clinical Practice Oncology 5 (12), 714-726, 2008 | 111 | 2008 |
| Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines AR Hussain, S Uddin, R Bu, OS Khan, SO Ahmed, M Ahmed, ... PLoS One 6 (9), e24703, 2011 | 100 | 2011 |
| Testis cancer O Khan, A Protheroe Postgraduate medical journal 83 (984), 624-632, 2007 | 76 | 2007 |
| Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an … CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, ... The Lancet Oncology 24 (4), 323-334, 2023 | 67 | 2023 |
